title: Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case report.
abstract: A newly approved oral fluoropyrimidine, TS-1, is a dihydropyrimide dehydrogenase (DPD)-inhibiting fluoropyrimidine (DIF) drug. We describe a case of interstitial pneumonia probably caused by TS-1. A peripheral blood lymphocytes stimulating test (DLST) with TS-1 demonstrated a substantial positive reaction. So far only three cases of TS-1-induced interstitial pneumonia have been reported but the relationship between interstitial pneumonia and TS-1 was demonstrated only in this case. Considering that interstitial pneumonia has also been reported with 5-FU, it is necessary in the future to clarify which component of this drug is directly related to interstitial pneumonia.
authors.affiliation: First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.
authors.forename: E
authors.initials: E
authors.lastname: Kurakawa
authors.forename: I
authors.initials: I
authors.lastname: Kasuga
authors.forename: S
authors.initials: S
authors.lastname: Ishizuka
authors.forename: T
authors.initials: T
authors.lastname: Yoshida
authors.forename: A
authors.initials: A
authors.lastname: Kunisawa
authors.forename: K
authors.initials: K
authors.lastname: Minemura
authors.forename: K
authors.initials: K
authors.lastname: Utsumi
authors.forename: K
authors.initials: K
authors.lastname: Ohyashiki
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D004338:Drug Combinations; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008297:Male; D010094:Oxonic Acid / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D013274:Stomach Neoplasms / Q000188:drug therapy; D005641:Tegafur / Q000009:adverse effects*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid